Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Sees Significant Drop in Short Interest

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was the recipient of a large decrease in short interest in the month of February. As of February 28th, there was short interest totalling 3,940,000 shares, a decrease of 14.9% from the February 13th total of 4,630,000 shares. Based on an average daily trading volume, of 895,400 shares, the short-interest ratio is currently 4.4 days. Currently, 7.1% of the company’s stock are short sold.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Royal Bank of Canada increased their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. StockNews.com lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th. Scotiabank increased their price objective on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, December 9th. Finally, HC Wainwright started coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They issued a “buy” rating and a $58.00 target price on the stock. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $56.57.

Insider Buying and Selling

In other news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the transaction, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.93% of the stock is owned by insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Atria Investments Inc grew its holdings in Agios Pharmaceuticals by 47.4% in the third quarter. Atria Investments Inc now owns 10,628 shares of the biopharmaceutical company’s stock valued at $472,000 after purchasing an additional 3,418 shares during the last quarter. Quest Partners LLC grew its stake in Agios Pharmaceuticals by 139.6% in the 3rd quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 1,283 shares during the last quarter. Intech Investment Management LLC acquired a new stake in Agios Pharmaceuticals in the 3rd quarter valued at about $892,000. Charles Schwab Investment Management Inc. increased its holdings in Agios Pharmaceuticals by 1.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 465,620 shares of the biopharmaceutical company’s stock valued at $20,687,000 after acquiring an additional 8,093 shares in the last quarter. Finally, Fisher Asset Management LLC raised its position in Agios Pharmaceuticals by 20.5% during the third quarter. Fisher Asset Management LLC now owns 855,328 shares of the biopharmaceutical company’s stock worth $38,002,000 after acquiring an additional 145,416 shares during the last quarter.

Agios Pharmaceuticals Stock Down 2.5 %

Shares of AGIO opened at $31.20 on Wednesday. The company has a market capitalization of $1.79 billion, a PE ratio of 2.75 and a beta of 0.90. Agios Pharmaceuticals has a 52-week low of $27.14 and a 52-week high of $62.58. The company has a 50-day simple moving average of $33.59 and a 200-day simple moving average of $41.56.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. On average, research analysts anticipate that Agios Pharmaceuticals will post -6.85 EPS for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.